These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20616115)

  • 1. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
    Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
    Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris.
    Schoonooghe S; Kaigorodov V; Zawisza M; Dumolyn C; Haustraete J; Grooten J; Mertens N
    BMC Biotechnol; 2009 Aug; 9():70. PubMed ID: 19671134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.
    Henderikx P; Coolen-van Neer N; Jacobs A; van der Linden E; Arends JW; Müllberg J; Hoogenboom HR
    Am J Pathol; 2002 May; 160(5):1597-608. PubMed ID: 12000712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering and expression of bibody and tribody constructs in mammalian cells and in the yeast Pichia pastoris.
    Schoonooghe S
    Methods Mol Biol; 2012; 899():157-75. PubMed ID: 22735952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
    Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
    Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial production and functional characterization of the Fab fragment of the murine IgG1/lambda monoclonal antibody cmHsp70.1, a reagent for tumour diagnostics.
    Friedrich L; Stangl S; Hahne H; Küster B; Köhler P; Multhoff G; Skerra A
    Protein Eng Des Sel; 2010 Apr; 23(4):161-8. PubMed ID: 20123884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
    Grinstead JS; Schuman JT; Campbell AP
    Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
    Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
    Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel bi-specific monoclonal antibody approach for tumour targeting.
    Koumarianou AA; Hudson M; Williams R; Epenetos AA; Stamp GW
    Br J Cancer; 1999 Oct; 81(3):431-9. PubMed ID: 10507767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
    Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
    Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives.
    Schoonjans R; Willems A; Schoonooghe S; Fiers W; Grooten J; Mertens N
    J Immunol; 2000 Dec; 165(12):7050-7. PubMed ID: 11120833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
    Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
    Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.